84 related articles for article (PubMed ID: 33649820)
1. Inhibitor of apoptosis protein Livin promotes tumor progression and chemoradioresistance in human anaplastic thyroid cancer.
Kim HK; Kim SA; Jung EK; Lee KH; Lee JK; Kang HC; Joo YE; Lim SC; Yoon TM
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649820
[TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis.
Crnković-Mertens I; Wagener N; Semzow J; Gröne EF; Haferkamp A; Hohenfellner M; Butz K; Hoppe-Seyler F
Cell Mol Life Sci; 2007 May; 64(9):1137-44. PubMed ID: 17437058
[TBL] [Abstract][Full Text] [Related]
3. Isolation of peptides blocking the function of anti-apoptotic Livin protein.
Crnković-Mertens I; Bulkescher J; Mensger C; Hoppe-Seyler F; Hoppe-Seyler K
Cell Mol Life Sci; 2010 Jun; 67(11):1895-905. PubMed ID: 20177953
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
[TBL] [Abstract][Full Text] [Related]
5. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.
Passaro C; Borriello F; Vastolo V; Di Somma S; Scamardella E; Gigantino V; Franco R; Marone G; Portella G
Oncotarget; 2016 Jan; 7(2):1500-15. PubMed ID: 26625205
[TBL] [Abstract][Full Text] [Related]
6. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
[TBL] [Abstract][Full Text] [Related]
7. Blocking CDK7-Mediated NOTCH1-cMYC Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
Doolittle WKL; Zhao L; Cheng SY
Thyroid; 2022 Aug; 32(8):937-948. PubMed ID: 35822558
[No Abstract] [Full Text] [Related]
8. Drug-induced inhibition of HMGA and EZH2 activity as a possible therapy for anaplastic thyroid carcinoma.
De Martino M; Pellecchia S; Decaussin-Petrucci M; Testa D; Meireles Da Costa N; Pallante P; Chieffi P; Fusco A; Esposito F
Cell Cycle; 2023; 22(23-24):2552-2565. PubMed ID: 38165007
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer.
Johnson JM; Lai SY; Cotzia P; Cognetti D; Luginbuhl A; Pribitkin EA; Zhan T; Mollaee M; Domingo-Vidal M; Chen Y; Campling B; Bar-Ad V; Birbe R; Tuluc M; Martinez Outschoorn U; Curry J
Semin Oncol; 2015 Dec; 42(6):915-22. PubMed ID: 26615136
[TBL] [Abstract][Full Text] [Related]
10. BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation.
Wang X; Ying T; Yuan J; Wang Y; Su X; Chen S; Zhao Y; Zhao Y; Sheng J; Teng L; Luo C; Wang W
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37184950
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression.
Ma Y; Cang S; Li G; Su Y; Zhang H; Wang L; Yang J; Shi X; Qin G; Yuan H
J Cell Physiol; 2019 Dec; 234(12):22260-22271. PubMed ID: 31081124
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
Cleere EF; Prunty S; O'Neill JP
Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells
Xiong L; Lin XM; Nie JH; Ye HS; Liu J
Nanotheranostics; 2021; 5(2):143-154. PubMed ID: 33457193
[No Abstract] [Full Text] [Related]
14. BUB1/KIF14 complex promotes anaplastic thyroid carcinoma progression by inducing chromosome instability.
Jin T; Ding L; Chen J; Zou X; Xu T; Xuan Z; Wang S; Chen J; Wang W; Zhu C; Zhang Y; Huang P; Pan Z; Ge M
J Cell Mol Med; 2024 Apr; 28(7):e18182. PubMed ID: 38498903
[TBL] [Abstract][Full Text] [Related]
15. Immunological characteristics of immunogenic cell death genes and malignant progression driving roles of TLR4 in anaplastic thyroid carcinoma.
Xu T; Zhu C; Song F; Zhang W; Yuan M; Pan Z; Huang P
BMC Cancer; 2023 Nov; 23(1):1131. PubMed ID: 37990304
[TBL] [Abstract][Full Text] [Related]
16. Thyroid hormone receptor α1: a novel regulator of thyroid cancer cell differentiation.
Hwang E; Doolittle WKL; Zhu YJ; Zhu X; Zhao L; Yu Y; Cheng SY
Oncogene; 2023 Oct; 42(41):3075-3086. PubMed ID: 37634007
[TBL] [Abstract][Full Text] [Related]
17. The m
Li P; Wang W; Zhou R; Ding Y; Li X
Clin Transl Med; 2023 Nov; 13(11):e1466. PubMed ID: 37983928
[TBL] [Abstract][Full Text] [Related]
18. Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy.
Wang J; Tan J; Wu B; Wu R; Han Y; Wang C; Gao Z; Jiang D; Xia X
J Nanobiotechnology; 2023 Oct; 21(1):374. PubMed ID: 37833748
[TBL] [Abstract][Full Text] [Related]
19. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.
Bible KC; Kebebew E; Brierley J; Brito JP; Cabanillas ME; Clark TJ; Di Cristofano A; Foote R; Giordano T; Kasperbauer J; Newbold K; Nikiforov YE; Randolph G; Rosenthal MS; Sawka AM; Shah M; Shaha A; Smallridge R; Wong-Clark CK
Thyroid; 2021 Mar; 31(3):337-386. PubMed ID: 33728999
[No Abstract] [Full Text] [Related]
20. Combined effects of octreotide and cisplatin on the proliferation of side population cells from anaplastic thyroid cancer cell lines.
Li Z; Jiang X; Chen P; Wu X; Duan A; Qin Y
Oncol Lett; 2018 Sep; 16(3):4033-4042. PubMed ID: 30128025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
